Research Analysts Set Expectations for PLX FY2026 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX – Free Report) – Investment analysts at HC Wainwright reduced their FY2026 earnings per share estimates for shares of Protalix BioTherapeutics in a report released on Wednesday, November 11th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $0.28 for the year, down from their prior estimate of $0.29. HC Wainwright currently has a “Buy” rating and a $12.00 price objective on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q4 2027 earnings at $0.02 EPS.

Protalix BioTherapeutics Stock Performance

NYSE PLX opened at $3.05 on Thursday. Protalix BioTherapeutics has a one year low of $1.65 and a one year high of $3.19. The stock has a 50-day moving average of $2.69 and a 200 day moving average of $2.45. The company has a market capitalization of $245.74 million, a price-to-earnings ratio of -23.46 and a beta of 0.01.

Institutional Investors Weigh In On Protalix BioTherapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in PLX. BlackRock Inc. purchased a new position in shares of Protalix BioTherapeutics in the 2nd quarter worth $9,429,000. Dimensional Fund Advisors LP grew its holdings in shares of Protalix BioTherapeutics by 932.7% in the first quarter. Dimensional Fund Advisors LP now owns 296,843 shares of the company’s stock worth $644,000 after acquiring an additional 268,099 shares during the period. Bank of New York Mellon Corp purchased a new stake in Protalix BioTherapeutics during the second quarter valued at $543,000. Russell Investments Group Ltd. increased its position in Protalix BioTherapeutics by 903.7% during the third quarter. Russell Investments Group Ltd. now owns 248,557 shares of the company’s stock valued at $686,000 after acquiring an additional 223,792 shares during the last quarter. Finally, Empowered Funds LLC purchased a new stake in Protalix BioTherapeutics during the third quarter valued at $271,000. Hedge funds and other institutional investors own 16.53% of the company’s stock.

Protalix BioTherapeutics Company Profile

(Get Free Report)

Protalix BioTherapeutics is an Israel-based biopharmaceutical company that develops and manufactures recombinant therapeutic proteins using its proprietary plant-cell expression system, ProCellEx. The company focuses on treatments for rare and chronic diseases and was founded in 1993. Its products include Elelyso (taliglucerase alfa), an enzyme replacement therapy for Gaucher disease, and Elfabrio (pegunigalsidase alfa), an enzyme replacement therapy for Fabry disease. Protalix developed Elfabrio in collaboration with Chiesi Global Rare Diseases; commercialization and distribution are handled through partner arrangements in multiple markets.

Read More

Earnings History and Estimates for Protalix BioTherapeutics (NYSE:PLX)

Receive News & Ratings for Protalix BioTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.